NEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (Nasdaq:
MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech
company, announced today the publication of the first
pharmacogenetic data on LSD to help personalize dosing. The study
results from a pooled secondary analysis of four Phase 1 studies
that each used a randomized, double-blind, placebo-controlled,
crossover design and were conducted at the University Hospital
Basel Liechti Lab, in Basel,
Switzerland.
The results of this study indicate that pharmacogenetic testing
prior to LSD-assisted treatment may inform LSD dose selection at
the individual patient level.
Dr. Matthias Liechti said, "This
is the first data on the pharmacogenetics of LSD. The results
indicate that a test of the metabolic function of a patient by
CYP2D6 phenotyping and genotyping can be used to adjust the dose of
LSD. Such information is important for the further development of
LSD into a medication and could ultimately help to personalize
patient treatment."
Key findings:
In vitro studies indicate that metabolic
cytochrome P450 isoforms, particularly CYP2D6, CYP1A2, and CYP2C9,
are involved in LSD metabolism, but clinical studies of the effects
of variations of these isoforms had not been conducted.
This study examined the influence of genetic polymorphisms of
important CYP enzymes on the pharmacokinetics and acute
psychological effects of LSD in healthy subjects. Common genetic
variants of CYPs including CYP2D6, CYP1A2, CYP2C9, CYP2C19, and
CYP2B6 were identified in 81 healthy subjects pooled from four
randomized placebo-controlled double-blind Phase 1 studies.
Genetically determined CYP2D6 functionality significantly
influenced the pharmacokinetics of LSD. Specifically, individuals
with no functional CYP2D6, known as poor metabolizers, had longer
LSD half-lives and approximately 75% higher parent drug and main
metabolite, 2-oxo-3-hydroxy-LSD, area under the curve blood plasma
concentrations compared with carriers of functional CYP2D6.
Additionally, non-functional CYP2D6 metabolizers exhibited
increased acute psychological effects and longer subjective effect
durations compared with functional CYP2D6 metabolizers.
No effect on the pharmacokinetics or acute effects of LSD were
observed with other CYP variations. These results indicate that
specific genetic polymorphisms of CYP2D6 significantly influence
the pharmacokinetic and subjective effects of LSD.
The study "Genetic influence of CYP2D6 on pharmacokinetics and
acute subjective effects of LSD in a pooled analysis" was published
in the Nature Scientific Reports and the full-text can be accessed
from the publishers at:
https://www.nature.com/articles/s41598-021-90343-y.
MindMed Executive President, Dr. Miri Halperin Wernli said, "The psychedelic
experience can be conceptualized as the facilitated transforming
encounter between one's fears and longings with the universe and
its network of living processes. This work with Professor Liechti,
indicating that genetic polymorphisms of CYP2D6 significantly
influence the pharmacokinetic and subjective effects of LSD, is an
illustration that biological and psychological transformation
processes may be deeply interwoven. When LSD is the chosen key to
open an opportunity for psycho-transformation and growth,
individual parameters such as one's own metabolization and
bio-transformation rhythm have to be carefully understood and taken
into consideration in order to allow the transformative effect to
happen in the most powerful and safe manner."
About MindMed
MindMed is a clinical-stage psychedelic
medicine biotech company that discovers, develops and deploys
psychedelic inspired medicines and therapies to address addiction
and mental illness. The company is assembling a compelling drug
development pipeline of innovative treatments based on psychedelic
substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine
derivative, 18-MC. The MindMed executive team brings extensive
biopharmaceutical experience to MindMed's approach to developing
the next generation of psychedelic inspired medicines and
therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO exchange under the symbol MMED. MindMed is also traded
in Germany under the symbol
MMQ.
Forward-Looking Statements
Certain statements in this
news release related to the Company constitute "forward-looking
information" within the meaning of applicable securities laws and
are prospective in nature. Forward-looking information is not based
on historical facts, but rather on current expectations and
projections about future events and are therefore subject to risks
and uncertainties which could cause actual results to differ
materially from the future results expressed or implied by the
forward-looking statements. These statements generally can be
identified by the use of forward-looking words such as "will",
"may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe", "potential" or "continue", or
the negative thereof or similar variations. Forward-looking
information in this news release include statements regarding the
genetic influence of CYP2D6 on pharmacokinetics, the acute
subjective effects of LSD, findings from the University Hospital
Basel Liechti Lab's Phase 1 studies, the metabolic function of
patients, the development of LSD into a medication, the potential
effect of variations of CYP2D6, CYP1A2, and CYP2C9, and the
Company's intended future business plans and operations, including
the development of psychedelic inspired medicines and experiential
therapies. Although the Company believes that the expectations
reflected in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities
regulatory authorities in all provinces and territories of
Canada and available under the
Company's profile on SEDAR at www.sedar.com and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing-301299501.html
SOURCE Mind Medicine (MindMed) Inc.